Analyses of the 31 patients whose PD-L1 detection results were available and the 25 patients who were eligible for TMB assessment indicated better clinical efficacy of ICIs for tumors with a higher PD-L1 expression (CPS ≥ 20) and a greater tumor mutation burden (> 12 mutations/Mb). The gene discussed is CD274; the disease is neoplasm.